| Liu, Lei |
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 864 | Europe, Canada, Japan, US, RoW | Dostarlimab, Placebo | GlaxoSmithKline | Neoplasms, Head and Neck | 05/28 | 07/29 | | |
| Terminated | 3 | 166 | Europe, Canada, Japan, US, RoW | Xevinapant (Debio 1143), IMRT, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Head and Neck Cancer | 08/24 | 08/24 | | |
NCT06601335: A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) |
|
|
| Recruiting | 3 | 510 | RoW | AK117 in combination with AK112, Placebo in combination with Pembrolizumab | Akeso | Head and Neck Squamous Cell Carcinoma | 01/27 | 10/27 | | |
NCT05076786: Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma |
|
|
| Recruiting | 2 | 28 | RoW | Chidamide, Epidaza, Etoposide + Cisplatin/Carboplatin, EP/EC regimen | Peking Union Medical College Hospital, The First Affiliated Hospital of Xiamen University, Harbin Medical University | Neuroendocrine Tumors, Neuroendocrine Carcinoma | 10/22 | 10/24 | | |
NCT05113355: Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm |
|
|
| Recruiting | 2 | 23 | RoW | Chidamide, Epidaza, Sintilimab, Tyvyt | Peking Union Medical College Hospital, The First Affiliated Hospital of Xiamen University, Harbin Medical University | Neuroendocrine Tumors, Neuroendocrine Tumor Grade 3, Neuroendocrine Carcinoma, Neuroendocrine Neoplasm | 11/22 | 11/24 | | |
NCT06378177: A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) |
|
|
| Recruiting | 2 | 64 | RoW | LVGN6051 Monoclonal Antibody Injection, LVGN6051, toripalimab Injection, Paclitaxel injection | Lyvgen Biopharma Holdings Limited | Head and Neck Squamous Cell Carcinoma | 10/27 | 10/27 | | |
AK112-IIT-C-W-0001, NCT06444009: A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 90 | RoW | Ivonescimab combined with TP, ITP, Cadonilimab combined with TP, CTP, Penpulimab combined with TP, PTP | Lei Liu | Head and Neck Squamous Cell Carcinoma | 12/25 | 12/27 | | |
| Recruiting | 2 | 50 | RoW | Adebrelimab | Sun Yat-sen University, Nanfang Hospital, Southern Medical University, West China Hospital, The First Affiliated Hospital of Xiamen University | Nasopharyngeal Carcinoma, Nasopharyngeal Cancer | 05/28 | 05/28 | | |
NCT05102006: Phase Ib/II Clinical Study of LBL-007 in Treatment of Advanced Malignant Tumors |
|
|
| Recruiting | 1/2 | 200 | RoW | LBL-007 Injection, LBL-007, Toripalimab Injection | Nanjing Leads Biolabs Co.,Ltd | Advanced Solid Tumor | 06/25 | 08/25 | | |
| Recruiting | 1/2 | 374 | Europe, Canada, Japan, US, RoW | Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil | Takeda, Takeda Development Center Americas, Inc. (TDC Americas) | Solid Neoplasms | 01/26 | 01/26 | | |
NCT05042908: Evaluation of LBL-003 Phase I Study in Patients With Advanced Malignancies |
|
|
| Completed | 1 | 18 | RoW | LBL-003 Injection, LBL-003 | Nanjing Leads Biolabs Co.,Ltd, Henan Cancer Hospital, Hunan Cancer Hospital, Shandong Cancer Hospital and Institute | Advanced Malignant Tumor | 04/23 | 04/23 | | |
| Recruiting | 1 | 96 | US, RoW | GQ1001 | GeneQuantum Healthcare (Suzhou) Co., Ltd., Conjugate Light (Australia) Pty Ltd | HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor | 03/24 | 05/24 | | |
| Recruiting | 1 | 92 | RoW | TQB2223 injection+ Penpulimab Injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Cancer | 01/25 | 01/26 | | |
| Completed | N/A | 4991 | NA | TACE | Tang-Du Hospital, Air Force Military Medical University, China, Army Medical University, The First Affiliated Hospital of Shanxi Medical University, Sun Yat-sen University, Shaanxi Provincial People's Hospital, Xijing Hospital, Health Science Center of Xi'an Jiaotong University | HCC, Transarterial Chemoembolization, Resection | 01/21 | 10/21 | | |
NCT04883177: Effectiveness and Safety of the COVID-19 Vaccination for Patients With Liver Disease (CHESS2101) |
|
|
| Completed | N/A | 1000 | RoW | | Hepatopancreatobiliary Surgery Institute of Gansu Province, LanZhou University, Huashan Hospital, The Sixth People's Hospital of Shenyang City, Xingtai City People's Hospital, Jinchang Central Hospital, Baoding People's Hospital, The Third People's Hospital of Zhenjiang City, Shanxi Bethune Hospital, Wuhan Jinyintan Hospital, Jincheng People's Hospital, The Third People's Hospital of Tibet Autonomous Region, People's Hospital of Ningxia Hui Autonomous Region, Fuling Central Hospital of Chongqing City, Hospital of the Chengdu Office of the People's Government of Tibet Autonomous Region, The Central Hospital of Lishui City, The Third People's Hospital of Linfen City, Yibin First People's Hospital, Jingzhou Central Hospital, Wuxi Fifth People's Hospital, Qingyang People's Hospital, The First Affiliated Hospital of Anhui Medical University, Beilun Hospital of Traditional Chinese Medicine, Henan Provincial People's Hospital, Qingdao Sixth People's Hospital, The First Affiliated Hospital of Xiamen University, Shandong Provincial Hospital, Beijing YouAn Hospital, The First People's Hospital of Taicang, The Third People's Hospital of Taiyuan, Tianjin Second People's Hospital, Tianjin Third Central Hospital, Qishan Hospital of Yantai City, Affiliated Hospital of Yunnan University, The First People's Hospital of Yunnan, The Fourth Affiliated Hospital of Zhejiang University, Third Affiliated Hospital, Sun Yat-Sen University, First Affiliated Hospital of Chongqing Medical University | COVID-19, Liver Disease, Vaccine Reaction | 01/22 | 05/22 | | |
NCT06346821: Tumor Treating Fields for Newly Diagnosed Glioblastoma: Two Emulated Trials With Chinese Multi-Hospital Based Real-World Data |
|
|
| Completed | N/A | 181 | RoW | Optune® (Tumor Treating Fields) | Sichuan University | Glioblastoma Multiforme | 04/24 | 04/24 | | |
TIPS, NCT06196723: Transjugular Intrahepatic Portosystemic Shunts Improve Survival in Patients With Cirrhosis and Recurrent Ascites |
|
|
| Completed | N/A | 462 | RoW | transjugular intrahepatic portal shunt | Tang-Du Hospital | Refractory Ascites | 02/24 | 02/24 | | |
NCT05976516: CXCL2/CXCL8 Promote Intervertebral Disc Degeneration |
|
|
| Recruiting | N/A | 40 | RoW | CXCL2/CXCL8 | Zhongda Hospital | Cytokine, Intervertebral Disc, Degenerative | 03/24 | 03/24 | | |
NCT06410716: Comparing Valve-regulated Pleural Drainage to Traditional Closed Chest Tube Drainage |
|
|
| Recruiting | N/A | 100 | RoW | Valve-regulated pleural drainage system | Peking Union Medical College Hospital, Ningbo Xinyue Medical Technology Co., LTD | Lung Cancer | 10/24 | 04/25 | | |
NCT06662071: A Research Protocol for Evaluating the Efficacy of Perfused Chemotherapeutic Agents for Bladder Cancer Based on Organoid Technology |
|
|
| Recruiting | N/A | 293 | RoW | Organoid culture | Qilu Hospital of Shandong University, The Second Hospital of Shandong University, The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Hospital, The Third Shandong Provincial Hospital, Taian City Central Hospital, Weifang People's Hospital, Binzhou Medical University, The Affiliated Hospital of Qingdao University, Jining First People's Hospital, Liaocheng People's Hospital, Linyi People's Hospital, Yantai Yuhuangding Hospital, Zibo Central Hospital, Dezhou People's Hospital, The Affiliated Hospital of Jining Medical University and Zaozhuang City, Qilu Hospital of Shandong University (Qingdao) | Bladder Cancer | 09/28 | 09/28 | | |
NCT04662918: Validation of CAGIB Score for In-hospital Mortality of Cirrhotic Patients With Acute Gastrointestinal Bleeding |
|
|
| Recruiting | N/A | 3000 | Europe, US, RoW | | Xingshun Qi | GastroIntestinal Bleeding | 12/24 | 12/24 | | |
| Recruiting | N/A | 102 | US | Orientation and Mobility Training with VR-IOMSs, Orientation and Mobility Training with COMS, No Orientation and Mobility Training | University of Alabama at Birmingham | Low Vision, Both Eyes | 03/25 | 06/25 | | |
RECOGNIZE-I, NCT05884008: Risk Evaluation by COronary CTA and Artificial intelliGence Based fuNctIonal analyZing tEchniques - I |
|
|
| Recruiting | N/A | 300 | RoW | | Ruijin Hospital | Coronary Artery Disease | 06/25 | 12/25 | | |
| Recruiting | N/A | 2000 | RoW | | Ruijin Hospital | Coronary Artery Disease | 09/25 | 12/25 | | |
| Recruiting | N/A | 147 | US | STEGA-MRI | Washington University School of Medicine, National Institute of Neurological Disorders and Stroke (NINDS) | Peripheral Nerve Injury Upper Limb, Healthy | 12/25 | 12/25 | | |
| Recruiting | N/A | 60 | US | Tumor collection via biopsy, Blood collection, Diffusion basis spectrum imaging (DBSI) magnetic resonance imaging (MRI), DBSI MRI | Washington University School of Medicine, National Cancer Institute (NCI) | Locally Advanced Cervical Carcinoma, Locally Advanced Cervical Cancer, Locally Advanced Pancreas Cancer, Locally Advanced Pancreatic Carcinoma, Locally Advanced Pancreatic Cancer, Cervical Cancer, Pancreas Cancer, Pancreatic Cancer, Cancer of the Cervix, Cancer of the Pancreas | 12/32 | 12/32 | | |
NCT04953533: Research and Development of a New Technology for Detection of Abnormal Excretion of Intestinal Uric Acid Involved in the Incidence of Gout |
|
|
| Recruiting | N/A | 800 | RoW | no intervention | Second Affiliated Hospital, School of Medicine, Zhejiang University | Gout, Hyperuricemia, Gut Microbiota, Uric Acid, Genetic Loci, Single Nucleotide Polymorphism, Feces | 01/23 | 12/23 | | |
| Zhuang, Yongze |
NCT05593575: Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease |
|
|
| Recruiting | 2 | 320 | RoW | SPH3127+SPH3127matching placebo+valsartan matching placebo, SPH3127+valsartan matching placebo, SPH3127 matching placebo+valsartan | Shanghai Pharmaceuticals Holding Co., Ltd | Diabetic Kidney Disease | 06/25 | 06/25 | | |
| peng, xiaona |
NCT05102006: Phase Ib/II Clinical Study of LBL-007 in Treatment of Advanced Malignant Tumors |
|
|
| Recruiting | 1/2 | 200 | RoW | LBL-007 Injection, LBL-007, Toripalimab Injection | Nanjing Leads Biolabs Co.,Ltd | Advanced Solid Tumor | 06/25 | 08/25 | | |
